Table 6 Clinical data of anti-GBM-positive HIV patients during follow-up
No | Gender | Stage | on the time of testing | follow-up after one year | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CD4 | Viral load | UPRO | UREA | CRE | eGFR | CD4 | Viral load | UPRO | UREA | CRE | eGFR | |||
(/μL) | (copy/ml) | (mmol/L) | (μmol/L) | (ml/min/1.73m2) | (/μL) | (copy/ml) | (mmol/L) | (μmol/L) | (ml/min/1.73m2) | |||||
P1 | Male | AIDS stage | 42 | TND | – | 6.4 | 109.3 | 69.1 | 58 | TND | – | 4.2 | 84.8 | 86.9 |
P2 | Male | Asymptomatic | 407 | 791,856 | – | 5.4 | 74.0 | 124.5 | 451 | 42 | 2+ | 5.0 | 84.5 | 111.6 |
P3 | Male | Asymptomatic | 440 | < 40 | – | 4.9 | 67.1 | 119.1 | 460 | TND | – | 6.2 | 73.1 | 114.2 |
P4 | Male | Asymptomatic | 776 | TND | – | 5.2 | 96.5 | 86.7 | 608 | TND | – | 5.2 | 106.9 | 76.8 |
P5 | Female | Asymptomatic | 459 | TND | – | 5.0 | 45.4 | 116.7 | 645 | TND | – | 5.6 | 51.9 | 110.8 |